Jane R Schwebke1, Jeannette Y Lee2, Shelly Lensing2, Susan S Philip3, Harold C Wiesenfeld4, Arlene C Seña5, Nikole Trainor3, Nincoshka Acevado6, Lisa Saylor6, Ann M Rompalo7, Robert L Cook8. 1. Department of Medicine, University of Alabama at Birmingham. 2. Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock. 3. San Francisco Department of Public Health, California. 4. Department of Obstetrics and Gynecology, Magee-Women's Hospital of University of Pittsburgh Medical Center, Pennsylvania. 5. Department of Medicine, University of North Carolina at Chapel Hill. 6. Family Health International, Durham, North Carolina. 7. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 8. Departments of Epidemiology and Medicine, University of Florida, Gainesville.
Abstract
BACKGROUND: Longitudinal studies have consistently found a significant association between bacterial vaginosis (BV) and acquisition of sexually transmitted diseases. However, there are limited prospective data to confirm these findings. METHODS: We conducted a prospective, randomized, open-label trial of home screening and treatment of young women with asymptomatic BV who were also at high risk for sexually transmitted diseases. These women were screened every 2 months for 12 months and randomized to treatment with oral metronidazole 500 mg twice daily for 7 days or observation alone. The primary outcome was the incidence of gonorrhea and/or chlamydia. RESULTS:A total of 1365 subjects were enrolled in the study across 10 sites. Adherence with mailing specimens obtained at home was excellent in both groups (84%-88%). The incidence of gonorrhea and/or chlamydia was 19.1 per 100 person-years (95% confidence interval, 15.1-22.1) for the treatment group and 18.5 per 100 person-years (15.1-22.8) for the observation arm, a difference that was not statistically significant. CONCLUSIONS:Young women were very amenable to home screening for BV, gonorrhea, and chlamydia. Treatment of asymptomatic BV with 1 week of oral metronidazole did not decrease the incidence of gonorrhea and/or chlamydia. CLINICAL TRIALS REGISTRATION: NCT00667368.
RCT Entities:
BACKGROUND: Longitudinal studies have consistently found a significant association between bacterial vaginosis (BV) and acquisition of sexually transmitted diseases. However, there are limited prospective data to confirm these findings. METHODS: We conducted a prospective, randomized, open-label trial of home screening and treatment of young women with asymptomatic BV who were also at high risk for sexually transmitted diseases. These women were screened every 2 months for 12 months and randomized to treatment with oral metronidazole 500 mg twice daily for 7 days or observation alone. The primary outcome was the incidence of gonorrhea and/or chlamydia. RESULTS: A total of 1365 subjects were enrolled in the study across 10 sites. Adherence with mailing specimens obtained at home was excellent in both groups (84%-88%). The incidence of gonorrhea and/or chlamydia was 19.1 per 100 person-years (95% confidence interval, 15.1-22.1) for the treatment group and 18.5 per 100 person-years (15.1-22.8) for the observation arm, a difference that was not statistically significant. CONCLUSIONS: Young women were very amenable to home screening for BV, gonorrhea, and chlamydia. Treatment of asymptomatic BV with 1 week of oral metronidazole did not decrease the incidence of gonorrhea and/or chlamydia. CLINICAL TRIALS REGISTRATION: NCT00667368.
Authors: Jennifer E Balkus; Barbra A Richardson; Lorna K Rabe; Taha E Taha; Nyaradzo Mgodi; Margaret Phiri Kasaro; Gita Ramjee; Irving F Hoffman; Salim S Abdool Karim Journal: Sex Transm Dis Date: 2014-02 Impact factor: 2.830
Authors: Maria F Gallo; Maurizio Macaluso; Lee Warner; Michael E Fleenor; Edward W Hook; Ilene Brill; Mark A Weaver Journal: Ann Epidemiol Date: 2011-12-20 Impact factor: 3.797
Authors: Robert L Cook; Lars Østergaard; Sharon L Hillier; Pamela J Murray; Chung-Chou H Chang; Diane M Comer; Roberta B Ness Journal: Sex Transm Infect Date: 2007-02-14 Impact factor: 3.519
Authors: Rebecca M Brotman; Mark A Klebanoff; Tonja R Nansel; Kai F Yu; William W Andrews; Jun Zhang; Jane R Schwebke Journal: J Infect Dis Date: 2010-11-10 Impact factor: 5.226
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Leslie S Massad; Charlesnika T Evans; Raymond Kang; Anna Hotton; Ruth Greenblatt; Howard Minkoff; Kerry Murphy; Christine Colie; Kathleen M Weber Journal: AIDS Res Hum Retroviruses Date: 2016-12-16 Impact factor: 2.205
Authors: Arlene C Seña; Jeannette Y Lee; Jane Schwebke; Susan S Philip; Harold C Wiesenfeld; Anne M Rompalo; Robert L Cook; Marcia M Hobbs Journal: Clin Infect Dis Date: 2018-06-18 Impact factor: 9.079
Authors: Angela Lovett; Arlene C Seña; Andrew N Macintyre; Gregory D Sempowski; Joseph A Duncan; Andreea Waltmann Journal: Front Microbiol Date: 2022-02-10 Impact factor: 6.064
Authors: Daniel Ruiz-Perez; Makella S Coudray; Brett Colbert; Karl Krupp; Hansi Kumari; Vitalii Stebliankin; Kalai Mathee; Robert L Cook; Jane Schwebke; Giri Narasimhan; Purnima Madhivanan Journal: Access Microbiol Date: 2021-05-04
Authors: P Madhivanan; K Krupp; M Coudray; B Colbert; D Ruiz-Perez; H Cui; N Bokulich; G Narasimhan; K Mathee; R L Cook; J Schwebke; D Roe Journal: Vaccine Date: 2021-07-20 Impact factor: 4.169
Authors: Makella S Coudray; Diana M Sheehan; Tan Li; Robert L Cook; Jane Schwebke; Purnima Madhivanan Journal: Sex Transm Dis Date: 2020-12 Impact factor: 3.868
Authors: Antonio Barrientos-Durán; Ana Fuentes-López; Adolfo de Salazar; Julio Plaza-Díaz; Federico García Journal: Nutrients Date: 2020-02-06 Impact factor: 5.717